Brief: 10X Genomics Q3 Gross Margin 70%
29/10/2024 20:05
Oct 29 (Reuters) - 10X Genomics Q3 operating income USD -41.5 million vs. IBES estimate USD -43.9 million. * Q3 net income USD -35.8 million vs. IBES estimate USD -41.7 million * outlook FY revenue USD 595-605 million
Recent news on 10x Genomics
See all newsBrief: 10X Genomics Announces New Collaboration To Advance Single Cell And Spatial Applications Across Solid Tumors And Blood Cancers
U.S. RESEARCH ROUNDUP-Autodesk, Hubspot, Oracle
Delaware jury finds Parse infringed three genetic-sequencing patents (updated)
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Brief: 10X Genomics Wins Patent Infringement Verdict Against Parse Biosciences